Annexon Stock Earnings Estimates Decreased by HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Annexon in a research note issued on Monday, October 19th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($0.28) for the quarter, down from their previous estimate of ($0.27). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Annexon’s Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.03) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at $0.58 EPS and FY2030 earnings at $1.36 EPS.

A number of other brokerages have also issued reports on ANNX. Citizens Jmp raised shares of Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. upped their price objective on shares of Annexon from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, September 30th. Wall Street Zen downgraded shares of Annexon from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Needham & Company LLC increased their target price on shares of Annexon from $11.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Monday, July 13th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $15.29.

Annexon Price Performance

Shares of ANNX opened at $3.83 on Wednesday. The firm has a fifty day simple moving average of $4.42 and a two-hundred day simple moving average of $5.13. Annexon has a twelve month low of $2.54 and a twelve month high of $7.18.

Annexon (NASDAQ:ANNX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04).

Institutional Trading of Annexon

Large investors have recently added to or reduced their stakes in the stock. Redmile Group LLC increased its position in Annexon by 44.8% during the 1st quarter. Redmile Group LLC now owns 14,549,768 shares of the company’s stock valued at $80,606,000 after purchasing an additional 4,499,124 shares during the period. BlackRock Inc. bought a new position in Annexon in the 2nd quarter worth $77,312,000. Bank of America Corp DE raised its holdings in Annexon by 165.3% in the 1st quarter. Bank of America Corp DE now owns 4,259,995 shares of the company’s stock worth $23,600,000 after purchasing an additional 2,654,414 shares in the last quarter. Siren L.L.C. purchased a new stake in shares of Annexon in the 1st quarter worth about $21,931,000. Finally, Palo Alto Investors LP purchased a new stake in shares of Annexon in the 2nd quarter worth about $16,833,594.

Insider Activity

In other Annexon news, CEO Douglas Love bought 26,065 shares of the firm’s stock in a transaction that occurred on Thursday, September 24th. The stock was bought at an average price of $3.83 per share, for a total transaction of $99,828.95. Following the completion of the acquisition, the chief executive officer directly owned 390,476 shares in the company, valued at $1,495,523.08. The trade was a 7.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 10.31% of the company’s stock.

Annexon News Roundup

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright raised its FY2027 EPS forecast to a loss of $0.69 from $0.74, FY2028 to a loss of $0.16 from $0.39, FY2029 to $0.58 from $0.03, and FY2030 to $1.36 from $0.45. The revisions imply a faster long-term path toward profitability, with positive EPS now projected beginning in FY2029.
• Positive Sentiment: The firm reiterated its Buy rating and $14 price objective, signaling substantial potential upside if Annexon’s pipeline and commercialization plans support the projected long-term earnings growth.
• Neutral Sentiment: HC Wainwright expects quarterly losses of approximately $0.20 per share throughout FY2027, followed by a $0.10 loss in the fourth quarter. Annexon is therefore still expected to remain unprofitable over the next several quarters.
• Negative Sentiment: HC Wainwright cut its Q3 2026 EPS estimate to a loss of $0.28 from $0.27, Q4 2026 to a loss of $0.24 from $0.22, and FY2026 to a loss of $1.03 from $0.99. These reductions point to somewhat weaker near-term financial expectations.
• Negative Sentiment: The company’s latest reported quarterly loss also missed consensus expectations, and shares remain below their 50-day and 200-day moving averages. Investors may remain cautious until Annexon demonstrates improved execution or provides stronger clinical and commercial updates. Annexon stock information

About Annexon

Annexon, Inc is a clinical-stage biopharmaceutical company developing therapies for diseases driven by activation of the classical complement pathway, an immune-system mechanism involved in inflammation and tissue damage. The company’s approach is designed to selectively inhibit complement activity while preserving other parts of the immune response.

Annexon’s pipeline has included ANX005, an investigational monoclonal antibody that targets C1q, an initiating protein in the classical complement pathway.